Hengrui Pharmaceutical (600276.SH): Application for marketing licensing of Heterripopa ethanolamine tablets was accepted

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” issued by the State Drug Administration, and the company's marketing license application for the new indications of hichipopa ethanolamine tablets was accepted by the State Drug Administration. Proposed Indications (or Functional Indications): This product is suitable for adult patients with chronic liver disease (CLD) related thrombocytopenia who wish to undergo elective invasive surgery (including diagnostic operations). CLD patients should not restore normal platelet counts by taking this product except in the scope of application.